Hennion & Walsh Asset Management Inc. Buys 71,006 Shares of Celcuity Inc. (NASDAQ:CELC)

Hennion & Walsh Asset Management Inc. raised its stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 97.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,032 shares of the company's stock after buying an additional 71,006 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.39% of Celcuity worth $1,885,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its stake in Celcuity by 42.7% in the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company's stock valued at $1,085,000 after purchasing an additional 19,811 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Celcuity by 9.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company's stock worth $272,000 after buying an additional 1,500 shares during the period. Rhumbline Advisers lifted its holdings in Celcuity by 27.7% during the second quarter. Rhumbline Advisers now owns 32,464 shares of the company's stock worth $532,000 after acquiring an additional 7,049 shares in the last quarter. Samlyn Capital LLC increased its holdings in shares of Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock worth $21,735,000 after acquiring an additional 637,190 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Celcuity by 40.0% during the second quarter. Marshall Wace LLP now owns 152,291 shares of the company's stock worth $2,495,000 after purchasing an additional 43,476 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 2.8 %

Shares of NASDAQ CELC traded down $0.32 during midday trading on Friday, reaching $10.93. The company's stock had a trading volume of 199,251 shares, compared to its average volume of 297,018. The stock has a 50 day simple moving average of $12.78 and a 200-day simple moving average of $14.97. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $405.83 million, a price-to-earnings ratio of -4.19 and a beta of 0.74. Celcuity Inc. has a fifty-two week low of $10.35 and a fifty-two week high of $22.19.

Analyst Upgrades and Downgrades

Several brokerages have commented on CELC. Stifel Nicolaus raised their target price on shares of Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Monday, October 7th. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Celcuity presently has a consensus rating of "Buy" and a consensus price target of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.